- Previous Close
13.83 - Open
13.79 - Bid --
- Ask --
- Day's Range
13.47 - 13.85 - 52 Week Range
13.47 - 37.18 - Volume
115,825 - Avg. Volume
221,615 - Market Cap (intraday)
151.27M - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
70.95 - EPS (TTM)
0.19 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 18, 2023
- 1y Target Est
15.75
Medifast, Inc., through its subsidiaries, operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. The company offers weight loss and weight management plans; and GLP-1 support plans that provide access to GLP-1 medications where clinically appropriate under the OPTAVIA brand name. It also provides bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups, as well as provides coaching support along with community, nutrition, and healthy habits, and helps people in their weight loss journey. It markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.
medifastinc.com504
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MED
View More
Performance Overview: MED
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MED
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MED
View MoreValuation Measures
Market Cap
147.44M
Enterprise Value
1.22M
Trailing P/E
70.95
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.25
Price/Book (mrq)
0.70
Enterprise Value/Revenue
0.00
Enterprise Value/EBITDA
0.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.35%
Return on Assets (ttm)
3.24%
Return on Equity (ttm)
1.02%
Revenue (ttm)
602.46M
Net Income Avi to Common (ttm)
2.09M
Diluted EPS (ttm)
0.19
Balance Sheet and Cash Flow
Total Cash (mrq)
162.34M
Total Debt/Equity (mrq)
7.68%
Levered Free Cash Flow (ttm)
6.53M
Research Analysis: MED
View MoreResearch Reports: MED
View MoreLowering target price to $21.00
MEDIFAST INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $23.00
MEDIFAST INC has an Investment Rating of HOLD; a target price of $23.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetLowering target price to $25.00
MEDIFAST INC has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about MED?
MEDIFAST INC has an Investment Rating of HOLD; a target price of $26.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice Target